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Abstract 
 
Intrauterine growth restriction (IUGR) is a complex global healthcare issue. Concerted research and 
clinical efforts have improved our knowledge of the neurodevelopmental sequelae of IUGR which has 
raised the profile of this complex problem. Nevertheless, there is still a lack of therapies to prevent 
the substantial rates of fetal demise or the constellation of permanent neurological deficits that arise 
from IUGR. The purpose of this article is to highlight the clinical and translational gaps in our 
knowledge that hamper our collective efforts to improve the neurological sequelae of IUGR. Also, we 
draw attention to cutting-edge tools and techniques that can provide novel insights into this disorder, 
and technologies that offer the potential for better drug design and delivery. We cover topics including: 
how we can improve our use of crib-side monitoring options, what we still need to know about 
inflammation in IUGR, the necessity for more human post-mortem studies, lessons from improved 
integrated histology-imaging analyses regarding the cell-specific nature of magnetic resonance 
imaging (MRI) signals, options to improve risk stratification with genomic analysis, and treatments 
mediated by nanoparticle delivery which are designed to modify specific cell functions. 
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Introduction 
 
Intrauterine (or fetal) growth restriction (IUGR, FGR) is caused by a heterogeneous set of maternal 
and fetal clinical pathologies. Stillbirth, neonatal mortality and poor neurological and cardiovascular 
outcomes are all too common consequences of IUGR. We do not have the clinical tests to reliably 
predict the onset of IUGR, or even to reliably detect it, when present in late gestation. A diagnosis of 
IUGR is simply the indication that the infant has a birth weight below their genetically predetermined 
potential, with no etiological meaning. Our understanding of the clinical progression of IUGR including 
the poor neurodevelopmental outcomes has increased due to improved imaging techniques, such as 
Doppler velocimetry and magnetic resonance imaging (MRI). Nevertheless, as a research community, 
we are still striving to understand the pathological mechanisms leading to the various subtypes of 
IUGR (discussed below). Increase of this knowledge is crucial for tailoring therapies to prevent or 
treat IUGR and, in particular to reduce brain injury. Highlighting the need for a continuing collective 
research efforts is that, depending on the specific definition of IUGR applied (discussed below), the 
incidence of IUGR is between 3-9% of pregnancies in high resource settings, but horrifically, in low-
resource settings, the rates are as high as 30% of pregnancies (Lee et al., 2017).  
 
The purpose of our review, written in a narrative form (as defined in McGaghie, 2015), is to highlight 
the gaps in our clinical and translational knowledge, and the weaknesses of our research methods 
that hamper our collective efforts to improve the neurological outcomes of those infants diagnosed 
with IUGR. Our opinions and interests are diverse - as authors we include clinicians working as 
obstetricians, neonatologists, and neonatal neurologists, plus researchers with expertise in fetal 
physiology and developmental neurobiology. We will focus on new cutting-edge tools and techniques 
that might provide novel insights into this disorder of fetal growth, and on technologies that offer the 
potential for better drug design and delivery. We will cover topics including maximising the benefit of 
data from scarce human post-mortem tissues, lessons from advanced histological analyses regarding 
the cell-specific nature of MRI signals, options to improve risk stratification with genomic analysis, 
and new treatments based on delivery of nanoparticles designed to modify cell-specific functions. 
 
What is IUGR?  
 
The issue of an optimal definition for IUGR has been called ‘one of the most common, controversial 
and complex problems in obstetrics’ (Unterscheider et al., 2013). Simply, IUGR is usually recognised 
when an infant appears to have failed to grow to its expected size – based on it genetically pre-
determined potential. Most surprisingly though, there is no universally applied definition of what 
threshold of body weight clearly defines an infant as IUGR, with birth weights at or below the 10th or 
the 3rd centile, and concomitant changes in placental blood flow and gestational age all taken into 
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account with varying frequencies across health care centres even within countries. An advance in 
bringing a universally recognised definition to the field was made with the recent publication of a 
Delphi procedure resulting in an agreed definition of IUGR (Gordijn et al., 2016). However, although 
a Delphi procedure is a well-established method for finding consensus, only 45 participants from 
across the entire world took part; 54% of these being from Europe, encompassing 37 member states 
with various population risk factors and health care paradigms. In addition, Asia and Australia were 
grouped as a single entity with only 10 opinions received from these diverse areas of the world. The 
Delphi procedure presented clinical variables and outcomes already known to be associated with 
IUGR and asked the participants to rank or stratify the importance of these. The end result was that 
somatic growth indices, umbilical artery pulsatility index, and absent end‐diastolic flow were the 
favoured diagnostic criteria. At this point we would like to highlight there is no pathophysiological 
meaning within the term IUGR (or FGR) as IUGR ultimately is a symptom, like the diagnosis of 
microcephaly (i.e., brain growth at or below 2 standard deviations from the mean). The term IUGR (or 
FGR) is as useful for understanding the disorder as if we used the term PRBS (poorly regulated blood 
sugar) in place of diabetes. The Delphi procedure offers no clarification on whether it is possible to 
stratify patients based on the underlying cause of their IUGR, although admittedly, this was not its 
purpose. However, we need to revaluate the criteria currently used to determine IUGR, (e.g., somatic 
growth, umbilical blood flow) some of which might well reflect compensation and adaptation to an 
underlying, unidentified causal mechanism. Additional measurements could include blood-based 
biochemical measures of inflammation, placentally-derived biomarkers, postnatal blood pressure and 
urine parameters, and additional biometrics such as skin folds, and skeletal phenotype. Meta-analysis 
of clinical data banks, together with studies on stored chorionic villi and maternal blood retained after 
routine clinical testing, and (albeit, complicated) the recruitment of further large prospective cohorts - 
could provide us with biochemical parameters that closely reflect the underlying causes of reduced 
fetal growth, and how these stratify with risk across the lifespan.  
 
How we name a disease has a significant bearing on how we then think about it, and ultimately, how 
we model and aim to treat it, so these issues of universal nomenclature are important; see 
commentaries by Dammann and colleagues (2011), and McIntyre and colleagues (2015) for the 
importance of classifying known causes, and not symptomatic outcomes. A recent summary of the 
definition(s) of IUGR as they have evolved over the past 30 years highlights three facts: (1) that a 
significant number of clinical studies on IUGR (11%) gave no definition of IUGR; (2) that ultrasound 
measurements of fetal biometrics, but not Doppler measurements of placental and/or fetal brain blood 
flows, have been increasingly used to define IUGR, and; (3) that overall the primary, consistently used 
characteristic of IUGR diagnosis is birth weight (Beune et al., 2018). This last observation highlights 
that we are missing opportunities to identify the early prenatal events that lead to IUGR, and therefore 
of developing our approaches to increase the efficacy of interventions, and the opportunity to prevent, 
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rather than repair brain damage and therefore to improve neurological outcomes for these infants via 
early identification. A further confounder in diagnosing IUGR is the lack of accurate gestational dating, 
as in many countries (including the USA) routine ultrasound dating scans are not available and 
estimates based on last menstrual period are generally unreliable.  
 
Maternal and fetal genetic factors are responsible for greater than 50% of the variance in birth weight 
(Lunde et al., 2007). As such, is it critical to separate healthy infants that are small for gestational age 
(SGA) due to inherent genetic factors from those with reduced growth that are at risk of sustaining 
neurological injury and metabolic dysfunction. Personalised growth charts, based on maternal and fetal 
characteristics (such as age, body weight, fetal sex and ethnicity), have improved our ability to differentiate 
IUGR and SGA infants, (for a commentary see Gardosi, 2014). While correcting for maternal parameters 
seems appropriate, perhaps correcting for ethnicity might normalise a socially disadvantaged group with 
higher rates of growth restriction and poor obstetric outcome. This was perhaps best reflected in 
INTERGORWTH 21 which recruited over 20,000 pregnant women from numerous countries around the 
world in regions where the health and nutrition of the mother were met and antenatal care was adequate, 
and they demonstrated that the growth parameters were similar regardless of ethnicity. 
 
IUGR is also classified as symmetric or asymmetric IUGR (Figure 2), dependent on the ratio of the 
head circumference to the abdominal circumference, which is increased in asymmetric IUGR. This 
categorisation is based on the idea of brain sparing arising (typically) from late-onset IUGR. Early-
onset IUGR (before 32 weeks post-conceptional age [PCA]) is more often associated with the 
symmetrical form of IUGR, and late-onset IUGR (after 31+6 weeks PCA) is more often associated 
with asymmetric IUGR. For further details on brain sparing and a discussion on the consequences 
and relationship between adaptive to maladaptive (compensatory vs decompensatory) processes, 
see the section on ‘Causes of IUGR’, below. There is also a third phenotype of IUGR reflecting the 
accumulated effects of early and late IUGR risk factors (Sharma et al., 2016). This mixed phenotype 
is observed predominantly in pregnancies complicated by peri-conceptual malnutrition, and then by 
placental dysfunction later in pregnancy. These infants are suggested to present with symmetric 
growth, but with severe signs of malnutrition, such as high numbers of scapula skin folds (Sharma et 
al., 2016). 
 
What are the outcomes associated with IUGR? 
 
IUGR foetuses are at increased risk of stillbirth, fetal compromise, early neonatal death and neonatal 
morbidity (Unterscheider et al., 2014). A vast literature including many works from DJ Barker and 
colleagues has demonstrated that the availability of physiological resources that support growth in 
utero, which include not only maternal nutritional status (Winder et al., 2011) but also placental size, 
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shape and metabolic efficiency, have effects that continue to have an impact on health throughout 
childhood and adult life (Martyn et al., 1996;Barker et al., 2011). Indeed, IUGR-born infants are prone 
to a range of health problems, including increased risk of cardiovascular diseases and 
neurodevelopmental disorders (Barker et al., 1989;Leitner et al., 2007).  
 
It has been difficult to compile outcome data from the many studies on IUGR, because in addition to 
the fact that IUGR includes an inconsistent, heterogeneous set of clinical characteristics and 
underlying aetiologies, postnatal data reporting includes further inconsistencies in patient selection 
and outcome parameters. To enable future trials to measure similar meaningful outcomes, the Core 
Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE) consortium is developing 
two core outcome sets – one for prevention and the other for treatment of IUGR (Healy et al., 2018). 
These guidelines will ensure the collection and reporting of a minimum dataset, agreed by stakeholder 
consensus that will reduce inconsistencies in the reporting of outcomes across relevant trials. For 
comprehensive reviews on IUGR-related brain injury, including specifics related to the type and 
severity of IUGR and outcomes, we refer the reader to Miller et al. (2016), Tolcos et al. (2017) and 
Gilchrist et al. (2018). Over all, infants that were born IUGR have a significantly increased risk of 
motor and sensory neurodevelopmental deficits, cognitive and learning impairments, and cerebral 
palsy (see papers above). In particular, in near-term and term infants the rates of cerebral palsy are 
higher in IUGR infants (16.5%) than the rates in infants exposed to birth asphyxia (8.5%) or 
inflammation (4.8%) (McIntyre et al., 2013). A common comorbidity of IUGR is preterm birth, and this 
confounds our understanding of the specific effects of IUGR on brain development and function 
(discussed below). In addition, the risk of delivering an IUGR baby is higher for woman with chronic 
hypertension, pre-eclampsia, low socioeconomic status, overt diabetes, anaemia, gestational 
diabetes mellitus, low pre-pregnancy body mass index, or hypothyroidism (Vijayaselvi and Cherian, 
2017). Whether each of these risk factors leads to a specific phenotype of outcome for the IUGR 
infant is still a matter that requires considerable study. A number of these risk factors and their causal 
role in IUGR is discussed further below.  
 
 
What are the causes of IUGR?  
 
The primary cause of IUGR is widely considered to be placental insufficiency; i.e., inability of the 
placenta to adequately support fetal growth. However, the causes of placental insufficiency are many 
and over-lapping, and include constricted spiral arteries and increased coagulation leading to fetal 
hypoxia (as in maternal hypertension), and inappropriate substrate availability due to maternal under-
nutrition or over-nutrition (Gaccioli and Lager, 2016;Vijayaselvi and Cherian, 2017) (see Figure 1). 
For the purposes of this review we won’t discuss in detail the relationship between IUGR and maternal 
Frontiers in Physiology/Endocrinology: "Adverse neurodevelopmental outcome following IUGR" REVISION 
 7 
drug use (alcohol, tobacco, cocaine etc) or the association with infectious agents, the so-called 
‘TORCH’ infections; Toxoplasmosis, Other (syphilis, hepatitis B, varicella-zoster virus, human 
immunodeficiency virus [HIV], parvovirus B19, enteroviruses, lymphocytic choriomeningitic virus etc.), 
Rubella, Cytomegalovirus, and Herpes simplex virus. However, these infections and exposure to 
environmental toxins often lead to a complex constellation of outcomes (microcephaly, facial 
abnormalities, intracranial calcifications, rash, jaundice, hepatosplenomegaly, elevated transaminase 
concentrations, and thrombocytopenia) which, although low in incidence in high-income settings 
(Khan and Kazzi, 2000), are significant in low resource settings (Accrombessi et al., 2018).  
 
Late versus early onset IUGR and the ‘head-sparing’ effect: In addition to linking IUGR to specific 
pathological processes, as discussed above we also classify IUGR as symmetric or asymmetric 
(Figure 2)(Gordijn et al., 2016), dependent on the ratio of the head circumference to the abdominal 
circumference of the infant. Asymmetric IUGR is the result of ‘brain sparing’, a process whereby brain 
growth is less affected than body growth due to the redistribution of cardiac output. While brain sparing 
does not completely prevent the damaging effects of IUGR on brain development (Flood et al., 
2014;Beukers et al., 2017), it is nonetheless associated with better neurological outcomes than when 
brain sparing does not occur (Scherjon et al., 2000). It is also worth noting that mortality is higher in 
IUGR with symmetric growth even after adjusting for possible cofounding factors (Flood et al., 2014). 
Brain sparing can be detected prenatally based on the Doppler pulsatility index (PI) in the middle 
cerebral artery (MCA); PI is reduced by the decreased cerebral resistance which allows a greater 
fraction of the cardiac output to perfuse the brain. However, this compensatory process of blood 
distribution can become ‘decompensatory’ because the increase of brain blood flow and blood volume 
themselves become damaging (Hernandez-Andrade et al., 2008). Understanding when and how the 
alteration of relative cerebral blood flow is switched from a compensatory to decompensatory 
response is clearly important for devising the most appropriate interventions and therapies. It is worth 
noting that brain sparing does not reduce the consequences of IUGR on later health, such as 
increased adiposity, diabetes, and cardiovascular risks, etc (reviewed in Sehgal et al., 2013;Devaskar 
and Chu, 2016).  
 
Maternal risk factors, especially diabetes, high body-mass-index and hypertension, are relevant risk 
factors for IUGR across both high- and low-income settings. This blurring of income-related 
demarcations is driven in part by changes in diet and lifestyle, such as adoption of a ‘western-style’ 
diet and changes in the nature of ‘work’ with more people employed in sedentary activities in urban 
centres across continents. An illustration of this is the increased risk for an IUGR infant when a woman 
is diabetic; in Africa the rate of diabetes in adults 25-64 years of age is at 15%, in India 9% and in 
Australia 5% (WHO, heath-topics, 2018). An increased body-mass-index is also a major risk factor 
for gestational diabetes that also associates with poor fetal outcomes. The effects of diabetes on the 
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placenta occur irrespective of the cause of diabetes and the careful management of blood sugar, and 
include thickening of the trophoblast basement membrane (Younes et al., 1996), which impairs 
oxygen and nutrient delivery. Diabetes is associated with a higher release of placental cytokines such 
as leptin, tumour necrosis factor-α (TNF-α) and Interleukin-6 (IL-6) (see references in, Pantham et 
al., 2015). Over-nutrition in the (apparent) absence of co-morbidities is also associated with poor 
placental development/function and poor fetal outcomes (recently reviewed in Howell and Powell, 
2017), and this has also been demonstrated in experimental models, including sheep, mouse, rat, 
and rabbit (Nivoit et al., 2009;Picone et al., 2011;Carr et al., 2012).  
 
An important link between maternal overnutrition, poor placental development and poor brain 
development is inflammation. Obesity is a known driver of systemic inflammation and 
neuroinflammation (see microglial section, below) (Cai, 2013), and a precise regulation of the 
maternal and fetal immune system is required for proper placental function and fetal brain 
development. Of note, adipose tissue produces adipokines, including the pro-inflammatory factors 
TNF-𝑎, IL-6 and MCP1 (macrophage chemotactic protein 1 also known as CCL2). This is considered 
to explain (at least, in part) why maternal obesity is associated with higher levels of circulating 
inflammatory mediators during pregnancy and dysregulated placental nutrient transport (Challier et 
al., 2008;Sureshchandra et al., 2018); such systemic and placental inflammatory effects can be 
reproduced by over-nutrition in pregnant sheep, leading to IUGR (Zhu et al., 2010;Yan et al., 2011).  
 
Preeclampsia increases the risks for IUGR 4-fold and is a leading cause of maternal and fetal death. 
Preeclampsia is a condition of vascular endothelial dysfunction and vasospasm that occurs after 20 
weeks of gestation that has its origins in inadequate trophoblastic invasion of the uterine vascular 
bed, in particular, of the spiral arteries. World-wide, preeclampsia occurs in 8-10% of pregnancies 
and this rate is consistent across high, middle- and low-income settings. The factors associated with 
the onset of preeclampsia include pregnancy at a young or advanced age, high maternal body-mass-
index and psychosocial stress. Preeclampsia is usually associated with IUGR, but early onset 
preeclampsia may be associated with an enlarged placenta and over-large birth weight. While reports 
show there are differences in placental function and biomarkers between IUGR and preeclampsia, 
there is overlap between the outcome in these disorders and understanding the similarities and 
differences will be useful for managing maternal and fetal risk (Crocker et al., 2003;McElrath et al., 
2003;Mayhew et al., 2004;McElrath et al., 2011;Odibo et al., 2011). 
 
In low resource settings malnutrition is a leading causal factor in IUGR, and all too often these IUGR 
infants are also delivered preterm adding to the burden of mortality and neurodevelopmental injury 
(Mavalankar et al., 1994;Mumbare et al., 2012). Malnutrition is linked not only to economic factors, 
but also to cultural and social norms that include young maternal age, and repeated and closely 
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spaced pregnancies. UNICEF estimates that in the most developed countries 7% of babies are of low 
birth weight, (encompassing prematurity and IUGR predominantly), whereas in less developed, and 
the least developed countries, rates of low birth weight deliveries increase to 16.5% and 18.6% 
respectively, representing more than 22 million babies annually. Although great improvements in 
health and well-being are being made, especially as part of the Millennium Development Goals, 
specific focus on how to overcome poor neurological outcomes for the infants born to these mothers 
is still greatly needed. For more details on IUGR in less well-developed countries please refer to these 
references: (Winick and Rosso, 1969;Mavalankar et al., 1994;Moormann et al., 1999;Boeuf et al., 
2008;Mumbare et al., 2012;Sharma et al., 2016;Lee et al., 2017). Trials of nutritional supplements 
(micronutrient-supplemented protein, balanced calorie supplements etc.) in women with an IUGR 
pregnancy identified in the 2nd trimester have failed to improve outcomes, and overall the literature 
supports pre- and peri-conceptional nutrition as a major determinant of fetal development and 
pregnancy outcome (reviewed in Liberato et al., 2013). 
 
What are the primary neuropathological processes in IUGR? 
 
Placental dysfunction: Early-onset IUGR is associated with high impedance uteroplacental perfusion 
and elevated umbilical artery blood flow resistance as measured by Doppler ultrasound (reviewed in 
detail by Dall’Asta et al,(2017). Late-onset IUGR is more common, occurring in 70-80% of IUGR cases 
and the diagnosis and monitoring of late-onset IUGR has been recently reviewed by Figueras and 
colleagues (2018). Overt placental pathology may be mild, or even absent in late-onset IUGR, and 
the Doppler parameters of umbilical artery blood flow may even be normal, but changes in brain blood 
flow dynamics, such as fetal middle cerebral artery impedance, may be reported indicating 
compensatory changes to cardiac output indicative of established IUGR. In addition to changes in 
uterine artery blood flow indicating high vascular resistance, placental studies reveal the important 
contribution of placental infarcts, and changes in placental amino acid and micro-nutrient transporters, 
and pathways for growth factor production, further support the concept of ‘functional’ placental 
insufficiency of IUGR (Avagliano et al., 2012;Chen et al., 2018). Based on these human studies, 
animal models of IUGR have been created that recapitulate aspects of the human condition 
(discussed below), and by and large demonstrate the link between the deprivation of oxygen, glucose, 
amino acid and growth factors to the slowing of fetal growth. In addition to this it is now apparent that 
the abnormal change in placental metabolism results in increased production of reactive oxygen 
species (ROS), aberrant activation of the complement cascade, re-programming of microglial 
phenotype (see below), and changes in the trajectory of brain maturation that include dysregulated 
neural cell proliferation, slower maturation of oligodendrocytes resulting in hypomyelination, and 
increased programmed (apoptotic) cell death (Miller et al., 2014;Rideau Batista Novais et al., 
2016;Kalanjati et al., 2017;Tolcos et al., 2018). We refer the reader to publications describing the 
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mechanisms underpinning the neuropathology of IUGR for more details on these processes (Ke et 
al., 2006;Tolcos et al., 2017;Zinni et al., 2018).  
 
In addition to the somewhat obvious link between the placenta as a source of cytotoxicity, there is the 
possibility that growth promoting cytokines and neurotrophic growth factors are altered with placental 
insufficiency. In addition to somatic growth factors such as IGF1, the placenta is a source of pregnene 
and androgen steroids that directly, or via metabolites such as allopregnanolone, promote and protect 
fetal brain development by promoting fetal sleep and quiescence (Dombroski et al., 1997;and 
references within Hirst et al., 2008). It has been hypothesized the allopregnanolone is an endogenous 
neuroprotectant, via its effect of global inhibition of CNS activity, that protects against antenatal brain 
injury (Hirst et al., 2006;Yawno et al., 2007;Fleiss et al., 2012).This field of steroid research has given 
rise to the notion that there is a ‘placenta-brain axis’ that reflects the co-ordinate development of the 
fetal adrenal gland, liver, and steroid metabolizing functions of the placenta (Wood, 2005;Hirst et al., 
2016). Neurosteroids derived from progesterone such as allopregnanolone interact with GABA-A 
receptors and increase central nervous system (CNS) inhibition (Belelli and Lambert, 
2005;Schumacher et al., 2014). In uncomplicated pregnancies there are high levels of neurosteroids 
such as allopregnanolone in the fetal brain immediately before birth, but these levels fall rapidly with 
removal of the placenta because they are cleared quickly from the circulation, and have a half-life of 
only minutes (Johansson et al., 2002). In the placenta of infants born preterm the activity of these 
neurosteroidogenic pathways is reduced, raising the possibility that the prenatal and postnatal paucity 
of allopregnanolone might affect brain development in these infants (Vu et al., 2009). In the serum of 
pregnant women carrying an IUGR foetus, levels of allopregnanolone are lower (Pecks et al., 2016), 
and in animal models of IUGR the neurosteroid systems (genes and proteins) are lower in the fetal 
brain (Westcott et al., 2008;Kelleher et al., 2011). Direct inhibition of allopregnanolone production 
during development causes brain injury (Yawno et al., 2009;Cumberland et al., 2017b) and lasting 
behavioural deficits (Cumberland et al., 2017a). It is thus reasonable to suggest that progesterone, 
and even allopregnanolone, should be replaced in preterm and IUGR infants to improve neurological 
outcomes (Hirst et al., 2014). For example, Ganaxolone is a synthetic analogue of allopregnanolone 
that has a long half-life, has shown promise as a seizure therapy in adults and children refractory to 
anti-seizure treatments, and in animal studies does not alter fetal viability, neonatal growth, and is 
without teratogenic or genotoxic effects (reviewed in (Hirst et al., 2014). Ganaxolone therapy should 
(like all drugs) be trialled in large animal models (powered for sex and with long term outcome) of the 
various types of IUGR that can now be modelled - for example, by delayed onset chronic hypoxia 
such as the single artery ligation (SUAL) sheep model (Castillo-Melendez et al., 2015); early onset 
placental insufficiency in piglets -(Kalanjati et al., 2017); maternal overnutrition before and during 
pregnancy in the sheep - (Wallace et al., 2000), . An important layer of safety data that needs to be 
obtained is the specific interaction that early treatment with ganaxolone might have on the 
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developmental switch of GABA receptors from excitatory to inhibitory (Ben-Ari et al., 2012). This event 
is predicted to be before 26 weeks’ gestation in humans and it might be expected that before this time 
that ganaxolone would induce, not supress, neuronal activity.  
 
Of the amino acids transported and metabolized by the placenta, tryptophan has a special 
significance (Badawy, 2015). It is an essential amino acid, but protein synthesis accounts for only a 
minor part of its fate, the greater part being committed to the kynurenine and serotonin pathways. 
Conversion of tryptophan to kynurenine via indoleamine 2,3-dioxygenase (IDO) in early pregnancy 
may be important for immune suppression and acceptance of the conceptus as an allograft (Badawy 
et al., 2016). Later in pregnancy the synthesis of kynurenine may be more important because it is the 
precursor of kynurenic acid, a physiological glutamate receptor antagonist, which acts as a 
neuroprotectant (Schwarcz et al., 2012). Both gene and protein expression of IDO and tryptophan 
2,3-dioxygenase (the second enzyme in the kynurenine to tryptophan conversion) are significantly 
lower in IUGR-affected placentas compared with controls (reviewed by, Murthi et al., 2017). IDO is 
an oxygenase, and its activity is downregulated in reduced oxygen conditions; demonstrated in ex 
vivo first and third trimester human placental explants exposed to lower oxygen (5-8% O2) or higher 
oxygen (20% O2) conditions. Exposure to lower oxygen levels reduced IDO mRNA and protein 
expression, and other kynurenine pathway enzymes and kynurenine output was also significantly 
reduced (Murthi et al., 2017). Inflammatory mediators, such as TNF-α, IL-1β and interferon-gamma, 
induce IDO expression thereby increasing tryptophan degradation to kynurenine, but with the result 
that pro-oxidant (e.g., 3OH-anthranilic acid) and glutamate agonist metabolites (e.g., quinolinic acid) 
are produced (Badawy, 2015). The impact of IUGR on the placental metabolism of tryptophan is not 
fully understood, but it can be seen from the above that placental insufficiency could have a significant 
impact on the fetal brain via alterations in the placental degradation of tryptophan. 
 
Tryptophan is also the precursor for the synthesis of serotonin (5-HT). Abnormal levels of brain 5HT 
have been linked to neurodevelopmental disorders such as autism spectrum disorder (ASD) 
(Whitaker-Azmitia, 2005), but when these abnormalities arise in humans (i.e. antenatally or  
postnatally?) is unclear. There is evidence from mouse pregnancies that placental 5-HT has an 
important role in early fetal brain development, in that the 5-HT needed for early forebrain 
development initially comes from the placenta (Bonnin et al., 2011). In early neurodevelopment 5-HT 
functions to regulate a number of key processes, including cell proliferation and neuronal 
differentiation, migration and synaptogenesis (Whitaker-Azmitia, 2005), and experiments in the 
mouse clearly show the free entry of 5-HT into the immature brain. However, by late gestation, there 
is a decrease of placental 5-HT synthesis in humans and mice as the raphe nuclei in the midbrain 
become competent and 5HT axons reach the forebrain (Bonnin et al., 2011) This co-ordinate change 
of 5-HT synthesis between the placenta and brain really does suggest the presence of a ‘placenta-
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brain axis’ which should be investigated more fully in experimental settings using where IUGR, 
placental insufficiency, and preterm birth can be modelled in animals with more relevance to human 
pregnancy. Specifically, an issue with traditional mouse studies is that the foetus is delivered at a 
stage of brain development equivalent to the start of the second trimester in the human; this makes 
studies of the last trimester fetal-placental axis impossible. However, peripherally synthesized 5-HT 
does not freely cross the blood-brain barrier in more fully developed (i.e. adult) brains (Jacobs and 
Azmitia, 1992). Goeden et al (2016) have also demonstrated the effects of mild maternal inflammation 
on placental tryptophan catabolism to 5-HT. Their findings suggest that maternal inflammation during 
human pregnancy may lead to increased 5-HT synthesis in the placenta and output to the foetus, 
resulting in abnormal serotonergic axon outgrowth into the developing forebrain. 
 
It is therefore evident that chronic placental hypoxia and inflammation affect the catabolism of 
tryptophan in the placenta. It is suggested that IDO may act as a ‘sink’ for superoxide, since IDO is 
known to utilize the superoxide anion as well as molecular oxygen for its oxygenase activity (Hayaishi 
et al., 1977). A decrease in IDO expression as a result of hypoxia may therefore lead to decreased 
clearance of superoxide and an inflammatory response, potentially increasing placental 5-HT 
synthesis, with consequences for brain growth (Azmitia, 2001). Alternatively, decreased kynurenine 
synthesis as a result of hypoxia may shift the tryptophan catabolism pathway in favour of 5-HT 
synthesis. Clearly, the full effects of IUGR and placental hypoxia on placental tryptophan catabolism 
are largely unknown but likely to be important for setting the chemical environment in the IUGR brain, 
and determining vulnerability to damage arising from hypoxia, oxidative stress, or inflammation. 
 
Inflammation and neuroinflammation: The term inflammation is used to describe the production of 
cytokines, chemokines, reactive oxygen species, and secondary messengers, together with the 
paracrine and autocrine effects of these factors. In the CNS, microglia and astrocytes are the primary 
drivers of inflammation, i.e., neuroinflammation. Both systemic inflammation and neuroinflammation 
play a central role in the pathophysiology of various forms of perinatal brain damage, as shown by 
observations from both animal models and the human neonate (Hagberg and Mallard, 2005;Van 
Steenwinckel et al., 2014;Lai et al., 2017). The levels of circulating cytokines in neonates born after 
IUGR are significantly increased on postnatal days 7 and 14 compared to levels measured in 
neonates without IUGR (Leviton et al., 2013;McElrath et al., 2013;Leviton et al., 2016). This postnatal 
systemic pro-inflammatory state following IUGR could be, at least in part, responsible for the frank 
brain damage and neurodevelopmental impairments detected in childhood in these individuals. 
Indeed, at the heart of the vulnerability of the immature brain lies the systemic up-regulation of pro-
inflammatory cytokines and the diffuse activation of cerebral microglia, the mediators of brain 
inflammation (Hagberg and Mallard, 2005). The activation of microglia and astrocytes occurs via 
inflammatory signals coming from the systemic circulation via receptors on endothelial cells and the 
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vagal nerve, and also by local pathogen- and damage-associated proteins (PAMPS and DAMPS, 
respectively) (reviewed in Carty and Bowie, 2011). In the context of IUGR, and in the absence of 
obvious pathogens, inflammation can come from at least two sources: (i) inflammation propagating 
from the placenta owing to the release of DAMPS due to tissue injury (see paragraph below), aberrant 
macrophage activation (Girard et al., 2014), and idiopathic villitis (Derricott et al., 2017), and; (ii) from 
direct effects of hypoxia or other nutrient deprivation or intoxication on the brain (Challier et al., 
2008;Zhu et al., 2010;Yan et al., 2011).  
 
Brain cell death, as a predicted consequence of hypoxia and other deprivations on the brain, would 
cause the release of DAMPS, such as HMGB1 (high mobility group box 1) that activate immune cells 
including microglia. Neuroinflammation, mediated by microglia, perturbs normal brain development 
directly by causing injury to cells such as maturing oligodendrocytes. In addition, an important set of 
developmental processes fulfilled by microglia is left undone when microglia are recruited to a 
neuroinflammatory response and this also damages the developing brain (see developmental 
dysfunction, below for further information on the role of microglia). A study of gene expression in 
microglia and oligodendrocytes in a model of protein restriction-induced IUGR has revealed a striking 
induction of inflammation-related genes in microglia accompanying the reduction in oligodendrocyte 
maturation and connectivity and functional deficits (Rideau Batista Novais et al., 2016). This was the 
first comprehensive study to link protein-restriction with neuroinflammatory-associated brain injury, 
and in the future, we will look for similarities in related animal models, and undertake human post-
mortem studies to look for these dysregulated pathways. We also point the reader towards two 
excellent reviews on the role of microglia/neuroinflammation in IUGR, one written by a team of experts 
in pre-clinical modelling and brain injury including observations of microglia and macro-gliosis in 
various animal models, Wixey, Bjorkman and colleagues (2017), and one from the perspective of 
experienced reproductive immunologists with a focus on maternal immune activation as a driver of 
microglial activation, Prins, Scherjon and colleagues (2018). 
 
It is worth noting that neuroinflammation (i.e., activated microglia) typically carries assumptions of 
completely maladaptive or damaging processes. However, less well understood processes of 
protection, repair and regeneration are also mediated by micro- and macro-glia, which occur at 
specific times after injury or insult (Faustino et al., 2011;Hamelin et al., 2016;Hanlon et al., 
2016;Kumar et al., 2016). Although there has not been sufficient study of microglial phenotypes in 
clinical or preclinical IUGR models, more knowledge on microglial activation (phenotypes and 
temporal regulation) will likely help the development of drugs and treatments that exploit and expand 
the reparative effects of microglia, while decreasing the negative effects of these cells. Harnessing 
microglia to regenerate the brain is an approach being applied in the field of multiple sclerosis and 
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adult neurodegeneration (Mikita et al., 2011;Miron et al., 2013;Song and Suk, 2017), and it clearly 
has a place in neonatal neurology.  
 
Developmental disturbance: The trajectory of brain development is altered by the presence of 
damaging stimuli, but also by the loss of cells, processes and factors that are important for brain 
building. As mentioned above, the causes and effects of IUGR include processes of inflammation, 
placental growth factor deprivation and hypoxia, which together affect the trophic actions of secreted 
factors such as serotonin, allopregnanolone, tryptophan and IGF1/2. In addition, we wish to highlight 
that the ‘distraction’ of microglia away from their normal physiological role in promoting proliferation, 
pathfinding, myelination and synaptogenesis will cause significant damage to the developmental 
trajectory of the brain (reviewed extensively in Hagberg et al., 2015;Pierre et al., 2017;Tay et al., 
2017;Prins et al., 2018) 
 
 
Managing the risks of continuing pregnancy versus preterm birth – the prenatal care team 
As there are currently no effective medical interventions for IUGR, management consists of close 
surveillance aimed at determining the most appropriate time for delivery. The definition of ‘most 
appropriate time’ is a question for which the prenatal team has few specific criteria, and balancing the 
risks of prematurity with the consequences of IUGR (including, stillbirth) remains a contentious issue. 
Clinical trials to determine the optimal time of delivery have focused on survival and immediate 
perinatal outcomes, and often lack long-term follow up or an exploration of what features of delivery 
result in optimal long-term outcomes and reduced neurodevelopmental complications. Recent 
randomised controlled trials (e.g., Growth Restriction Intervention Trial [GRIT]; Trial of Randomised 
Umbilical and Fetal Flow in Europe [TRUFFLE]) have helped to shed light on delivery parameters of 
IUGR babies that lead to improved long-term outcomes. Both studies had a primary outcome of 
neurodevelopmental delay at 2 years of age.  
 
The GRIT study randomised women at 24 to 36 weeks PCA to early or delayed delivery and included 
patients when the clinician was in equipoise about whether they needed delivery. ‘A priori’ parameters 
set to determine when patients would be delivered were not used in this study. This agnostic approach 
can be seen as a benefit, as retrospective analysis could shed light on novel parameters common to 
infants who did well, but it is also difficult, as the motivation for the clinician’s decisions are not easy 
to describe or document, and may not have been adequately captured in the analysis. There was 
generally only a 4-day delivery interval delay between randomising the participants to immediate 
versus delayed delivery. The 2- and 7-year follow-ups did not show a difference in 
neurodevelopmental outcome between groups (discussed further below) 
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The TRUFFLE trial was performed to examine whether parameters set ‘a priori’ for delivery are 
effective in optimising delivery outcomes. Participants with IUGR diagnosed at 26 to 32 weeks PCA 
with an elevated umbilical artery pulsatility index were randomised to delivery based on: (1) reduced 
cardiotocography fetal heart rate short-term variation (STV-CTG); or (2) early ductus venosus (DV) 
changes via doppler; or (3) late ductus venosus changes. They found that more infants randomly 
assigned to delivery based on late changes in the ductus venosus (95%) were free of neurological 
impairment compared to those assigned to cardiotocography (85%), but this was accompanied by a 
non-significant increase in perinatal and infant mortality. They therefore concluded that delivery based 
on late changes in DV flow might reduce long-term neuro-impairment. When the actual criteria for 
delivery in these cohorts was dissected it became clear that the majority of patients in the delivery for 
DV changes were being delivered based on the safety net criteria of spontaneous decelerations in 
the fetal heart rate. When the two cohorts being delivered for DV changes were combined the 
neurodevelopmental outcomes at 2 years of age were more favourable compared to those delivered 
based on STV CTG changes. Therefore, optimal neurodevelopmental outcomes may result if delivery 
of very preterm patients is restricted until late changes arise in the DV with a caveat of delivery 
whenever the CTG is abnormal (Bilardo et al., 2017;Visser et al., 2017). 
 
Severe growth restriction at term is also associated with poor neurodevelopmental outcomes (Gilbert 
and Danielsen, 2003). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT) 
assessed the impact of immediate delivery versus expectant management in patients with growth-
restricted foetuses at term. The follow-up at 2 years of age demonstrated similar neurodevelopmental 
gains. However, when assessed by gestation at birth, those in the lowest 2.3 percentile had 
significantly more neurodevelopmental compromise on an ‘ages and ‘stages’ questionnaire compared 
to those with a higher birth weight centile. Indeed, 43% of babies born with a birth weight centile below 
2.3 had an abnormality on the their ‘ages and stages’ questionnaire compared to 29% of those born 
at <10th centile and 13% of those with a birth weight greater than the 10th centile. This is consistent 
with a number of cohort studies demonstrating that low birth weight resulted in increased learning 
difficulties, defects in speech, neurological deficits and behavioural problems (van Wyk et al., 2012).  
 
Brain injury in the preterm born IUGR infant – the postnatal care team 
 
The incidence of spontaneous preterm birth in pregnancies with severe IUGR is 2 to 3-fold greater 
than the incidence of pregnancies with appropriate fetal growth (Lackman et al., 2001). In addition, 
antenatal care focuses heavily on fetal growth monitoring in order to identify pregnancies with poor 
growth that may benefit from a timely, planned preterm delivery to improve outcomes. However, the 
contribution of antenatal compromise versus the postnatal complication of being born preterm, or 
potential interactions between the two, in contributing to the neurodevelopmental sequelae of IUGR 
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is still unclear. This is important for the clinical decision on when to deliver, when IUGR is diagnosed 
antenatally. 
 
In a large cohort study comparing more than 1400 preterm IUGR infants with age-matched AGA 
controls from 25 to 32 weeks PCA, the incidence of severe intraventricular haemorrhage (IVH) in 
each gestational age group was similar, but prematurely born IUGR neonates had increased morbidity 
and mortality (Garite et al., 2004). On the other hand, preterm birth has been suggested to override 
the effects of IUGR per se on neurological outcomes (Gortner et al., 2003;Yanney and Marlow, 2004), 
with the impact most marked for births at the earlier gestational ages. In early-onset IUGR, the 
gestational age at delivery shows a consistent independent relationship with parameters of motor 
development with a maximum impact for infants delivered before 28 weeks PCA (Sung et al., 
1993;Shand et al., 2009;Padilla et al., 2010), independent of the severity of attrition of growth and the 
degree of cardiovascular and biophysical deterioration. In the GRIT study which randomly allocated 
women to early or delayed delivery in the presence of IUGR, and when the obstetrician was unsure 
whether to deliver, 98% of these patients (n=376) completed a 2-year follow-up, revealing that the 
rate of cerebral palsy was greater for patients delivered prior to 31 weeks PCA, and prematurity-
related complications were important contributors to this risk (Thornton et al., 2004). Notably, the 
relationship between gestational age, IUGR and motor deficits suggests the impact of IUGR becomes 
more apparent with delivery at a later gestation (Walker et al., 2011). The large prospective EPIPAGE 
(Etude EPIdémiologique sur les Petits Ages Gestationnels, epidemiologic study of early gestation 
ages) study (>5000 births) examined neurological outcomes in school-age children that were born 
AGA or IUGR (<10th centile for birth weight) at 24–28 weeks or 29–32 weeks PCA, and found similar 
cognitive deficits in AGA and IUGR infants born at 24–28 weeks PCA, but much less in AGA infants 
born at 29–32 weeks (Guellec et al., 2011). This clearly indicates the importance of in utero brain 
maturation up to at least 32 weeks PCA. The rate of neurocognitive deficits in the moderately preterm 
infants with IUGR was around 40% and was identical to the incidence of neurocognitive deficits in 
extremely preterm infants (Guellec et al., 2011), indicating that the impact of intra-uterine and extra-
uterine adverse conditions may be similar on the developing brain in early third trimester. However, 
a limitation of the EPIPAGE study was stratification of infants by birth weight alone, with no supporting 
evidence for IUGR.  
 
Consistent with these findings, another study using neuroimaging showed that at 6 years of age, both 
extremely preterm infants (born before 28 weeks) and moderately preterm IUGR infants (born after 
28 weeks), had decreased brain connectivity (measured using MRI fractional anisotropy) when 
compared with moderately preterm AGA controls, which in turn is associated with poorer socio-
cognitive performance (Fischi-Gomez et al., 2015). IUGR infants born moderately preterm and 
assessed at term equivalent age also demonstrated reduced cerebral cortex grey matter volume and 
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lower scores in attention-interaction availability, compared to appropriately grown preterm infants 
(Tolsa et al., 2004). Again, these observations support the importance of in utero brain maturation. 
 
Interestingly, the rates of several prematurity-associated neonatal diseases in IUGR versus AGA 
infants also vary with the gestational age at birth. In preterm infants born at or before 28 weeks PCA, 
the rates of IVH, respiratory distress syndrome and necrotizing enterocolitis are largely unaffected by 
IUGR. From then on, all adverse outcomes including IVH increase in IUGR compared with AGA 
premature infants, suggesting a need for closer surveillance for IUGR in the moderate and late 
preterm infants (Gilbert and Danielsen, 2003;Ortigosa Rocha et al., 2010). Such findings are of 
concern since late preterm births account for the vast majority of preterm births. Studies on infants 
born at later preterm to term gestational ages suggest that impaired fetal growth increases the risk 
for low intellectual performance (Geva et al., 2006;Leitner et al., 2007;Figueras et al., 2009). 
Comparing monozygotic twin pairs born after 32 weeks PCA, the growth-restricted twin is at increased 
risk for low cognitive performance at school age or in adulthood compared to the appropriately grown 
twin (Edmonds et al., 2010). In addition, a further study in twins has quantified the effects of low birth 
weight, showing that a 500g increase in (term) birth weight results in a 2% increase in total brain 
volume, grey matter volume and white matter volume, and a 2-point increase in IQ (Raznahan et al., 
2012).  
In summary, the gestational age at delivery has a remarkable impact for IUGR infants who are born 
extremely preterm, such that the prematurity-related complications “override” the effects of IUGR on 
neurodevelopmental outcome. For the moderately late preterm infants, the independent impacts of 
IUGR and prematurity on neurodevelopmental outcome becomes more apparent. Altogether, these 
studies highlight that we need more information on when to deliver IUGR babies, and the criteria on 
which to base this decision.  
 
Clinical trials and presumptive therapies 
 
We wish to acknowledge the enormous contributions of researchers and clinicians in bringing 
therapies to clinical trials and generating the preclinical data to support these transitions, although the 
purpose of this article is not to review all of these. We will highlight some trials and their outcomes as, 
while we have no conclusively effective therapies as yet, we can learn a great deal about improving 
patient stratification and the efficacy in drugs with shared mechanisms of actions. For example, a 
recent double-blind randomised study using dydrogesterone, a synthetic progestogen, has reported 
increased birth weight, and decreased MCA resistance index in idiopathic IUGR (Zarean et al., 2018), 
supporting the therapeutic use of progesterone replacement suggested in preclinical studies in guinea 
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pigs (Palliser et al., 2016). Specifically, in this human trial weight increased by approximately 50% in 
the treatment arm, versus 23% in the control arm. Although these effects are promising, this was a 
single centre, small study (89 participants), recruiting early and late IUGR (range 28-35weeks of 
gestation) with no postnatal follow-up, thus further work remains to be done. The action of 
dydrogesterone includes effects that altogether increase myometrial perfusion and 
immunomodulation by increasing progesterone-induced blocking factor (PIBF) levels (Kalinka and 
Szekeres-Bartho, 2005). PIBF is secreted by peripheral lymphocytes from healthy pregnant women, 
and it has important immunomodulatory functions that appear to protect foetuses from resorption and 
therefore plays a role in the maintenance of pregnancy, most likely by inhibiting NK lymphocytes and 
producing a dominant TH2 cytokine response (Polgar et al., 2004); hence, many poor pregnancy 
outcomes including miscarriage and preterm birth are linked to low PIBF levels. Manipulation and 
control of PIGF levels in pregnancy is therefore a priority for researchers. 
 
The STRIDER-UK study (multicentre, randomised, double-blind, 156 participants) tested the use of 
sildenafil in women with severe early-onset IUGR and found that treatment did not prolong pregnancy 
or cause any adverse effects, but did not improve pregnancy outcomes, (Sharp et al., 2018). However, 
this study is part of a more extensive international study, and in isolation, it does not have the power 
to adequately assess outcomes in this very high-risk cohort (45% of recruited infants in this study 
died) (Smith, 2018). A meta-analysis (9 studies, total of 576 treated patients) has shown that arginine 
supplementation increases gestational length and birth weight in IUGR pregnancies, except for infants 
born preterm (<32 weeks PCA) with severe IUGR (Chen et al., 2016); there were no reported side 
effects. The proposed mechanisms of action of arginine include the increased production of placental 
insulin that acts as a fetal trophic factor.  
 
Creatine may also be a potential treatment for IUGR (Dickinson et al., 2014;Ellery et al., 2016), with 
recent studies showing a positive correlation of birth weight to placental creatine load (Dickinson et 
al., 2016), and the discovery that the human placenta expresses the enzymes to synthesize and 
transport creatine (Ellery et al., 2017). Creatine is an energy substrate which protects ATP turnover 
during periods of oxidative stress (Wallimann et al., 2011) and as such may be a potential prophylactic 
treatment for IUGR outcomes (Dickinson et al., 2014;Ellery et al., 2016). Creatine readily crosses the 
placenta in humans and some other omnivores (but not in sheep, an herbivore), suggesting that 
maternal creatine supplementation could be used to increase placental creatine transfer and promote 
foetal growth in a hypoxic uterine environment. Supporting data include a number of pre-clinical 
studies(Adcock et al., 2002;Ireland et al., 2008;Ireland et al., 2011). Whilst there has been extensive 
animal research suggesting creatine’s potential to protect the foetus against periods of oxygen 
deprivation in several animal models, and there is a strong rationale for moving towards clinical trials 
for maternal creatine supplementation to reduce or prevent IUGR, no intervention studies have yet 
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been undertaken in pregnant women. IUGR is also proposed to be a disorder of insulin-like growth 
factor-1 (IGF-1) deprivation (discussed below). Of particular note is an extensive preclinical study of 
prenatal IGF-1 treatment in a sheep model of IUGR (41 controls, 66 IUGR + saline, 28 IUGR + IGF-
1, powered for sex-specific analysis and long term follow-up) which show that prenatal IGF-1 
treatment improves prenatal and postnatal indices of growth and biochemical dysfunction in IUGR 
(Wali et al., 2012;Spiroski et al., 2018). 
 
Overcoming the hurdles to progress  
 
Early markers for IUGR screening: a challenge faced by researchers and clinicians.  
Less than 30% of infants with a birth weight <10th percentile are detected during pregnancy 
(Verlijsdonk et al., 2012;Fratelli et al., 2013). Infants born after undiagnosed IUGR have 2-9 times 
higher risk of perinatal death and severe neurological complications to those diagnosed prenatally 
(Richardus et al., 2003;Evers et al., 2011;Gardosi et al., 2013).  
 
The current, commonly used antenatal assessment of IUGR is examination of the symphysiofundal 
height, and this has a sensitivity of just 17% and a positive predictive value of 20% (Sparks et al., 
2011). Once a red flag has been raised, even selective ultrasound and universal ultrasound perform 
poorly with a sensitively of 20% and 57% respectively (Sovio et al., 2015). This perhaps reflects the 
larger calibre vessels and reduced downstream resistance of the late preterm placenta that means 
that the umbilical artery Doppler parameters are rarely abnormal; indeed, most adverse events in late 
pregnancy occur in foetuses with normal Doppler readings (Baschat, 2010). However, as mentioned 
above, FGR babies assessed at term age will often demonstrate abnormal middle cerebral artery 
(MCA) blood flow represented by a reduced MCA pulsatility index (PI) due to ‘brain sparing’. A more 
sensitive and specific measure of foetal well-being may be the cerebral-placental PI ratio, which is 
calculated as the MCA PI divided by umbilical artery PI. This parameter has improved the sensitivity 
for detecting babies at risk of adverse perinatal outcome including perinatal mortality, admission to 
NICU, low 5-minute Apgar score and caesarean for fetal distress(Cruz-Martinez et al., 2011;Oros et 
al., 2011;Flood et al., 2014).  
 
Given the importance of placental insufficiency for the origin of IUGR, blood-based markers in the 
mother that relate to early-onset placental insufficiency are logical starting points for identifying 
biomarkers that detect IUGR. Biomarkers are molecules, genes, or a particular combination of these 
by which a pathological or physiological process is identified. Recent reports of biomarkers in maternal 
blood related to early-onset placental insufficiency include pregnancy-associated plasma protein-A 
(PAPP-A), alpha-fetoprotein (AFP), inhibin A, placental growth factor (PlGF), uric acid, and free beta- 
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or total human chorionic gonadotropin (Lausman et al., 2013;Girard et al., 2014). For example, a two 
to three-fold increase in late-onset IUGR is noted in women who were found to have elevated first 
trimester PAPP-A and elevated second trimester AFP (Morris et al., 2008). Combining maternal risk 
factors, biochemical markers such as ADAM12 (A Disintegrin and Metalloprotease-12) and placental 
protein-13, plus abnormal uterine artery waveforms for the prediction of late-onset IUGR (with a false 
positive rate of 5%), provides a sensitivity of 61% for IUGR at < 37 weeks but unfortunately only 32% 
for IUGR at > 37 weeks (Karagiannis et al., 2011).  
 
The use of these putative biomarkers (and the development of new biomarkers) is constrained by the 
absence of robust baseline data on their expression and function. We could overcome these problems 
with population profiling and further basic research into the mechanisms underlying typical placental 
development and function. Biomarkers for identification and stratification could improve outcomes 
even with current clinical practices, and are likely to have two additional benefits: firstly, prenatal 
treatment options (e.g., intra-amniotic IGF-1 - (Spiroski et al., 2018) are showing great promise, and 
biomarkers would identify those needing therapy; and secondly, by avoiding treatment of healthy 
babies and the risk of complications arising from newly developed prenatal therapies.  
 
In utero assessment of brain structure and metabolism is now possible, and these techniques have 
been applied to cohorts of IUGR infants (Story et al., 2018). These studies aim to understand the 
underlying pathology, but also to determine biomarkers as indicators of pathology and outcome. For 
example, in 19 IUGR and 25 non-complicated pregnancies, T2-weighted MRI allowed for the 
assessment of neuropathology and magnetic resonance spectroscopy allowed for analysis of indices 
of cell membrane and myelin formation (choline), glycolytic enzyme activity as an indicator of cerebral 
hypoxia (lactate), and for cerebral mitochondrial function (NAA) (Story et al., 2018). Of the 15 infants 
with complete data sets in the IUGR arm, 3 died in utero, and only 2 had an uncomplicated neonatal 
course. However, MRI was not sensitive enough to detect injury in any of the 15 IUGR infants before 
delivery (median scan age of 27+6 weeks PCA). Interestingly, fetal brain lactate levels were elevated 
in three control infants with normal progress of growth, birth and outcomes. Increased brain lactate 
has previously been considered a hallmark of hypoxic changes, but lactate may also play a role as 
an energy source in the developing brain (Baud et al., 2003). The authors suggest that the altered 
magnetic resonance spectroscopy parameters represent changes in mitochondrial metabolic status, 
and these warrants further study in a preclinical model as a novel therapeutic approach. This study is 
a valuable example of how these still tricky and expensive prenatal screening techniques could be 
applied to larger cohorts, but whether this effort can provide invaluable data on the mechanism of 
damage and criteria for risk stratification will require further research.  
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Circulatory biomarkers based on the detection of microRNAs (miRs), mitochondrial DNA (mDNA), 
cell-free RNA (cfRNA) and exosomes could also have diagnostic value, but remain to be fully 
validated. Two recent studies demonstrate how these new analytic approaches provide early 
diagnostic biomarkers for preterm birth and preeclampsia. Firstly, (Ngo et al., 2018) demonstrated 
that a panel of seven cfRNAs present in the maternal blood had utility in predicting preterm birth with 
an AUC (area under the curve) of 0.81. Similarly, Jelliffe-Pawlowski and colleagues (2018) used a 
25-target screen of serum proteins that, together with maternal risk factors, predicted preterm birth 
with an AUC of 0.806. Both studies might be said to be limited by low patient numbers and a lack of 
ethnic diversity in the patient groups, but this multi-marker approach seems to increase sensitivity 
and specificity compared to previous mono-marker approaches, and improvements (decrease) in the 
time needed to perform such analyses means that effective bedside screening is becoming a reality.  
 
A further elaboration on the multi-marker approach is the application of personalized risk-based 
screening methods that combines maternal factors and biomarkers, as in the combined use of uterine 
artery Doppler, maternal risk factors and serum biomarkers. This approach, taken as part of a study 
nested in clinical trial for pre-term preeclampsia (ASPRE, Aspirin for Evidence-Based Preeclampsia 
Prevention) (Poon et al., 2018), showed clearly that prospective screening for preterm preeclampsia 
by means of the FMF (Fetal Medicine Foundation) algorithm, which combines maternal factors and 
biomarkers at 11-13 weeks' gestation, was better at predicting disease risk than current biometric 
criteria. 
 
A holistic versus mechanistic view of modelling IUGR – how to improve the validity of our 
models 
An important question when modelling any disease or disorder is whether it is necessary for the 
phenotype (in this case a reduction in body and brain weight) to be the same as observed clinically if 
we don’t know that the mechanism of injury has been faithfully reproduced. Also, how much 
importance should we place on the phenotype (body and brain weight) being matched if we have to 
apply an injury/perturbation (in type or magnitude) that is not clinically relevant? In the case of IUGR 
there has been a proliferation of animal models that produce fetal growth restriction, but often by 
means that have limited clinical reality; e.g., abrupt and late onset reductions of uterine or umbilical 
blood flows. These procedures do produce hypoxia-induced cell death, and various complex 
inflammatory processes that help us to understand and look for effects in IUGR infants, but they are 
of limited use in understanding how IUGR and placental dysfunction actually arise in human 
pregnancy. Perhaps, with our increasingly detailed knowledge of how and when placental dysfunction 
in IUGR occurs (Mills et al., 2005;Leeuwerke et al., 2016;Murthi et al., 2017), we could aim to model 
these specific changes, and this would be valuable in the collective move towards developing 
therapies that can be applied early in pregnancy. We will below describe some of the common 
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approaches to modelling IUGR and some suggestions for how these could be altered to add to our 
collective data on how to prevent IUGR, and treat or repair the damage caused by IUGR. 
 
Surgical interventions that reduce perfusion of the maternal or fetal side of the placenta: The seminal 
study demonstrating that poor placental growth itself causes attrition of fetal growth is that of 
Wigglesworth (1964). Since that time there has been a proliferation of models of IUGR, predominantly 
focused on fetal/neonatal weight and based on the conceptual paradigm that it is uteroplacental 
perfusion that determines placental function, which in turn determines fetal growth and the 
vulnerability of the fetal brain to damage. These models of IUGR include (but are not limited to): acute 
onset hypoxia/ischemia (uterine artery ligation), progressive onset hypoxia/ischemia (uterine artery 
restriction); and placental damage/reduction (inert microsphere injection, partial placentotomy). 
However, these approaches offers little consideration to the idea that the foetus(es), or the feto-
placental compartment might themselves be the source of physiological changes that cause the 
typical uterine hyperaemia and the appropriate increase of utero-placental perfusion with increasing 
gestation. Evidence of this type (and almost forgotten) was acquired nearly 50 years ago by 
Christopher Bell in guinea pigs who showed that progesterone produced by the placenta causes a 
loss of constrictor adrenergic nerves in uterine blood vessels, and simultaneously induces synthesis 
of a vasodilator mechanism not present in the non-pregnant uterine vasculature (Bell and Brown, 
1971;Bell and Malcolm, 1978). Hence, there is a good reason to think that a cause of IUGR is the 
failure of the placenta to adequately modify the uterine circulation to support time-dependent fetal 
growth. As such, more work needs to be done on the differences in feto-placental signalling as a 
driver for poor utero-placental vascular development across gestation.  
 
In all experimental studies to date, the attention is almost always directed to the fetal effects, with few 
observations made of maternal or placental physiology, especially the clinical conditions usually 
associated with IUGR, such as uterine artery and myometrial remodelling, immune regulation of 
trophoblast implantation, placental metabolism per se, and the causes of placenta infarction and 
abruption, etc. A chief mechanism by which we should validate animal models of IUGR should be to 
measure uterine blood flow, as is done clinically. Admittedly, historically this was not easy to do in 
rodents, although it is increasingly possible due to advancements such as ultrafast doppler. We now 
have the ability to measure these clinical indices and to associate them with fetal outcomes as we 
attempt to better understand this relationship.  
 
Poor placental structure and function – from the beginning: Placental insufficiency is a process that 
evidence suggests is present from the earliest stages of trophoblast invasion, supported by the 
observation of abnormal levels of inflammatory and placental factors from the 1st trimester with poor 
pregnancy outcomes (Odibo et al., 2011; and reviewed in Kane et al., 2014). From the time of 
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trophoblast invasion into the endometrium, the uterus undergoes phenomenal modification (Myatt, 
1992;Regnault et al., 2002), increasing in weight and internal volume by approximately 16- and 500- 
fold respectively, together with major re-modelling of the uterine vasculature (as discussed above) to 
create a low resistance, non-reactive vascular bed. It is perhaps not surprising that these features 
have received less attention as determinants of IUGR because, except for non-human primates, these 
key features of pregnancy are not present in the commonly used laboratory animals. However, 
comparative studies of more unusual species, like the Spiny Mouse (Accomys caihrinus) reveal that 
unlike in the conventional rodent that there is a large vascular contribution to the fetal membranes 
originating from the umbilical vessels close to the fetal surface of the placenta (unpublished 
observations). As such, studying basic process of placentation in small species such as these may 
be a useful start to developing models of early-onset placental dysfunction that mimics what is seen 
clinically (Wali et al., 2012;Chan et al., 2014;Chen et al., 2018). Non-traditional species such as the 
spiny mouse, gerbil, and guinea pig studied from the time of conception offer advantages such as a 
relatively long gestation (from 39 to ~67 days), and the birth of offspring where development of the 
major organ systems is largely complete at the time of birth. For the spiny mouse in particular, an 
additional advantage is that the foetal adrenal gland produces dehydroepiandosterone and cortisol 
(Dickinson et al., 2005;Quinn et al., 2013;Quinn et al., 2016), with evidence of the presence of a feto-
placental unit as in humans, and not present in other rodent-like animals, or sheep. 
 
A clear example of how a candidate mechanism has been effectively applied to model IUGR is the 
knockout of IGF2 production in the mouse placenta. Levels of the IGF proteins are often reduced and 
IGF1 binding proteins increased in the placentas of IUGR human pregnancies (Nawathe et al., 2016), 
although this is not consistently found (Abu-Amero et al., 1998). The regulation of IGF signalling is a 
complex balance between the IGFs and their binding partners that regulate bioavailability during 
pregnancy, including in IUGR (reviewed in Martin-Estal et al., 2016). Mice born from dams with a 
placenta-specific IGF2 gene knock out (KO) have clearly reduced body weight, brain injury, and 
lasting cognitive and metabolic phenotypes with postnatal development. The mating of the IGF2 
placenta-specific KO mice with the endothelial NOS (eNOS) KO mice provides an interesting example 
of the cross-talk between (putative) pathological mechanisms. As expected, the phenotype of these 
two KOs was additive (more severe IUGR), but the diminished placental nutrient transport typically 
observed in the eNOS KO mice was not seen in the IGF2-eNOS double crossed mice (Dilworth et al., 
2012). The basis of the application of the eNOS KO mice to IUGR research is that the absence of 
eNOS reduces the capacity of the maternal vascular to accommodate the changes in blood flow 
necessary for adequate placentation, and that the dams are hypertensive (including with proteinuria) 
as observed in women with pre-eclampsia, a risk factor for IUGR. Thus, it was concluded that a 
“multiplicity of dysfunction” probably underlies IUGR in women, so the multiple facets of vascular 
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dysfunction in this mouse line would be useful to assess placental hypoxia with free radical formation, 
reduced placental nutrient transport capacity, and reduced fetal growth (Kusinski et al., 2012). 
 
Assessment of the epigenetic landscape of the eNOS and IGF2 genes from IUGR placental tissues 
shows that epigenetic modifications are present and might be drivers of gene dysregulation (Krause 
et al., 2013). However IGF2 gene expression changes and methylation changes of IGF2 are not 
consistently reported in clinical studies, One of the negative clinical studies found neither gene or 
methylation changes the cohort was older mothers (39-40 years of age), although changes in 
placental methylation are only detectable with the techniques used when substantial differences are 
present (Leeuwerke et al., 2016). Alternatively, this negative study is evidence that methylation and 
gene expression changes in IGF2 are not present in the first trimester but evolve over time, and so 
this important study that warrants repeating with larger and more diverse cohorts.  
 
Immunological dysfunction: There is clear evidence that the immune system in women with an IUGR 
pregnancy differs compared to those without IUGR (Alahakoon et al., 2018). This study found that 
peripheral monocytes in women with an IUGR pregnancy had a more classically anti-inflammatory 
profile than monocytes from women with an uncompromised pregnancy. In addition, when peripheral 
blood mononuclear cells from women with IUGR and normal pregnancies were stimulated with 
trophoblast antigen (Raghupathy et al., 2012), a greater pro-inflammatory reaction occurred in women 
with an IUGR pregnancy. When these dysfunctional processes first arise in pregnancy, and their 
impact on early placentation, would be interesting to pursue further, albeit requiring large cohorts of 
prospectively recruited, not-yet-pregnant women - a difficult task, but one with important public health 
outcomes. This information would then be possible to overlay into more specifically focussed animal 
models.  
 
As pointed out by Sir Peter Medawar many years ago (Medawar, 1952) it is clear that immune 
modulation is a fundamental response to conception that allows implantation and persistence of the 
foetus as a foreign allograft, and a response likely to be shared by humans and laboratory animals. It 
is a process that involves a phenotypic transformation of decidual macrophages and natural killer 
cells that occurs in parallel with remodelling of the vasculature adjacent to the implantation site. As 
such, it is possible that these shared features could be used to drive spontaneous cases of IUGR in 
non-human pregnancies. Indeed, some cross-breeding of mice of mixed genetic background has 
been found to produce IUGR of varying degrees, together with, as for most clinical situations, other 
complications of implantation, uterine re-modelling, and pathophysiology suggesting preeclampsia in 
the dam (Girardi et al., 2006;McKelvey et al., 2016). These ‘immune’ models have been shown to 
have similarities pathological changes as occurs in the human IUGR placenta in the trophoblast 
remodelling protein Formyl peptide receptor-2 (FPR2; Lappas et al., 2018), and a dysfunction of 
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decidual arteriolar remodelling (Dixon et al., 2006) such as that associated with pre-eclampsia and 
IUGR (Labarrere et al., 2017). Thus, we may have experimental models at hand which will aid in the 
understanding of the origin of IUGR together with the other obstetric problems that usually accompany 
it. A strength of this approach is that each of the parents and the offspring are immunologically 
competent, and it is only the combination of the fetal and maternal tissues that is abnormal. This 
model will require further assessment of fetal brain phenotypes to support the similarities in placental 
immune dysfunction to the human, but it promises to be valuable to assess therapies to minimise the 
neonatal morbidities that IUGR produces. 
 
Finally, we would like to highlight the comments made by Dr Taimur Saleem and colleagues from 
Karachi, Pakistan that “Concerted efforts should be made to gather indigenous data about the risk 
factors of IUGR that are more pertinent to our population. Evidence-based recommendations deduced 
from such data sets are more likely to be successful and valid” (2011). Although they were addressing 
the need for improved medical services, we think this comment also points to the need for 
improvements in preclinical modelling to be “population specific”. This specificity must take into 
account not just high versus low income, but aetiologies and conditions specific to local care centres, 
and this is where in-depth epidemiology needs to take a more prominent role in guiding preclinical 
research.  
  
 
Human neuropathological studies and how they need to play a bigger role in the study of IUGR 
 
The emergence of modern medicine was firmly based on pathology and post-mortem examinations, 
and while never being able to identify mechanisms of disease or injury per se, have been invaluable 
as the basis for setting diagnostic criteria and the effectiveness of treatments and interventions. The 
expectations of many that modern imaging, genetics, and -omics would make pathology obsolete has 
been a significant error of 21st-century science, and in neonatology it was high-quality neuropathology 
studies by groups in Portland (OR, USA), Paris (France), and Boston (MA, USA) (Back et al., 
2001;Billiards et al., 2008;Verney et al., 2012) that were persuasive in changing our understanding of 
the genesis of perinatal brain injury over the past 20 years. Specifically, these foundational studies 
provide the basis for interpreting MRI studies, and for designing improved animal models to test 
neuroprotective strategies. This is important because most IUGR babies survive, and the injuries 
present in very severe IUGR foetuses may not be representative of the major population of IUGR 
infants.  
 
It is indeed worth highlighting a number of human studies; this is not exhaustive but is intended to 
allow us to remark on what we have learnt, and what we need to add to the field. Studies from 
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Samuelsen and colleagues (2007) show a reduction in the numbers of cells in the brains of IUGR 
infants; these infants displayed brain sparing (relative increase in brain weight to body weight) but still 
had significantly lower brain weights. In this study, control foetuses acquired an average of 173 million 
cells per day from mid-gestation to term, and the IUGR foetuses acquired only 86 million new cells 
per day. Samuelsen et al’s exhaustive cell counting assessment (reviewed in, Larsen, 2017) supports 
the findings of two studies from over 30 years ago which used a lower total DNA content to infer a 
reduction in cell numbers (Winick and Rosso, 1969;Chase et al., 1972). Samuelsen’s conjectures that 
his data supports the hypothesis that the reduction in head circumference in IUGR is due to reduced 
proliferation rather than cell death is provocative, but needs to be confirmed by objective assessment 
of cell death and proliferation.  
 
Another set of studies includes a concerted effort by researchers based primarily at the Mater 
Hospitals in Brisbane, Australia, that included 37 asymmetric IUGR cases (weight <3rd centile) 
identified from a series of 225 stillbirths (Burke et al., 1997). This first study, over 20 years old now, 
critically demonstrated the importance of cell death, and to a lesser extent astrogliosis, in the IUGR 
brain. It is worth noting that although the analysis was limited to hematoxylin and eosin assessment 
of cell death, and in some cases glial fibrillary acidic protein for astrocytosis, that even with the 
expertise of a neuropathologist no injury was found in 5 of the 37 brains. Of these 5 ‘uninjured’ IUGR 
brains, 4 were from infants below 26 weeks PCA – does this suggest an important window for 
treatment specificity? Striking limitations of this study are that there was no breakdown of the specific 
gestational ages of the infants, no body or brain weight data, and no case-by-case description of the 
findings, making it very difficult to draw further conclusions. These authors overcame many of these 
limitations in a more recent publication (Burke and Gobe, 2005) using brains from the first cohorts 
and sourced from a further 305 stillbirths where they assessed cell death with three separate markers. 
This more recent study clearly showed that third trimester stillborn foetuses with both IUGR (weight 
<3rd centile) and placental infarction (<5% of total placental villus surface) had neuronal apoptotic 
changes in regions including the pons and the frontal and temporal cortex. These studies involved 
the use of controls that were stillborn but had neither IUGR nor placental infarction. Staining for micro- 
or macrogliosis or proliferation was not included, unfortunately.  
 
The value of continuous neuro-monitoring to understand risk for the IUGR infant  
 
Much has already been reported on the neuroimaging findings of IUGR infants and their relationships 
to neurodevelopmental delay. However, neuroimaging such as MRI can only be done at specific time-
points and is not applicable as continuous neuro-monitoring to reveal temporal changes with impact 
on clinical conditions and to guide management.  
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Cerebral haemodynamic measurements in the IUGR foetus 
With advancing fetal hypoxia and compromise, the cerebral haemodynamic response involves two 
components – firstly an initial stage of increased cerebral blood flow aimed at protecting the brain 
(brain sparing), followed by a second decompensatory stage that is associated with brain injury, and 
probably due to the increased cerebral blood volume (Hernandez-Andrade et al., 2012). At the early 
stages (i.e., brain sparing) blood flow (CBF) of the frontal lobes is increased, perhaps with the effect 
of protecting higher cognitive functions, but under chronic and more severe circumstances this 
change is lost and CBF is diverted to deeper (more essential?) structures such as the basal ganglia 
and the brainstem (Hernandez-Andrade et al., 2008). Also, in the IUGR foetus there appears to be a 
loss of cerebral vasoreactivity; using prenatal Doppler sonography, a subset of IUGR foetuses did not 
show the expected rise in cerebral resistance in response to maternal hyperoxygenation, suggestive 
of impaired cerebrovascular regulation. Indeed, these ‘non-responders’ had a higher risk of being 
delivered for fetal distress, indicating that they were more compromised (Arduini et al., 1989).  
 
It is interesting that there is an increased incidence of stroke in adults born with low birth weight. The 
association between low birth weight and adult stroke was most pronounced for individuals with 
relatively increased head size, suggestive of in utero conditions that induce brain sparing (Martyn et 
al., 1996). It is very plausible that these mechanisms of increased adult stroke are due to vascular 
remodelling secondary to the shear stress and wall tension, leading to structural changes in the 
vascular wall (Langille, 1996). Thus. understanding IUGR-associated cerebral haemodynamic 
changes has implications for improving brain health even in adults. 
 
Cotside cerebral haemodynamic measurements: cerebral blood flow and oxygenation 
Studies in IUGR infants have made the following important observations:  
-  increased CBF on the first day of life (Baenziger et al., 1994);  
- reduced cerebrovascular resistance and persistent dilatation of the cerebral arteries (van Bel 
et al., 1986;Nishimaki et al., 1993);  
- higher regional cerebral oxygen saturation and reduced cerebral oxygen extraction within the 
first 24 hours (Ishii et al., 2014) and up to 3 days of age (Cohen et al., 2016); and, 
- cerebral haemodynamic parameters normalise within a few days of birth (van Bel et al., 
1986;Baenziger et al., 1994;Ishii et al., 2014).  
To date there is little postnatal research investigating the relationship between cerebral 
haemodynamics after birth and neurological injury in IUGR infants; this is an area of need as there is 
evidence to indicate that the altered cerebral haemodynamics that exist in the IUGR foetus persist 
postnatally. Notably, cerebral oxygenation has been shown to predict neurodevelopmental outcome 
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in preterm infants (Alderliesten et al., 2014). Moreover, fluctuations of cerebral oxygenation and 
oxygen extraction have also been related to the occurrence of intracranial haemorrhage in preterm 
infants (Alderliesten et al., 2013;Noori et al., 2014). Finally, if CBF remains elevated when the neonate 
is no longer exposed to a hypoxic environment, the increased CBF could cause hyperoxia within the 
fragile brain and contribute to further neurological damage (Gerstner et al., 2008). 
 
Cotside cerebral haemodynamic measurements: cerebral autoregulation 
Autoregulation is the ability of the cerebral vasculature to maintain reasonably constant CBF despite 
fluctuations in cerebral perfusion pressure which are mainly affected by changes in systemic blood 
pressure, and it is likely that autoregulation is impaired in sick preterm neonates and this contributes 
to the cerebral ischaemic and haemorrhagic injury (Brew et al., 2014). As IUGR foetuses are often 
delivered preterm, and due to the vascular structural and functional changes set in place by the ‘brain 
sparing’ response to IUGR, these infants are theoretically at risk of impaired autoregulation, resulting 
in cerebral hypo- or hyperperfusion when systemic blood pressure fluctuates. In case of prolonged 
brain sparing due to chronic hypoxaemia, maximal cerebral vessel dilatation may have already been 
reached and may persist after birth, which would further limit protective autoregulatory responses. In 
addition, IUGR neonates appear to have higher blood pressures compared to their AGA peers 
(Sehgal et al., 2013;2014), theoretically contributing to risk of cerebral hyperperfusion and 
haemorrhage in the presence of a pressure-passive cerebral circulation; indeed, this has been shown 
in IUGR lambs where, compromised structural integrity of the cerebral microvasculature leading to 
cerebral haemorrhage has been demonstrated (Castillo-Melendez et al., 2015). Despite its clinical 
significance, to date no study has investigated cerebral autoregulation in human IUGR neonates.  
 
Cotside electroencephalographic (EEG) monitoring 
Cerebral electrographic activity can serve as an indicator of neuronal integrity, organisation, and the 
differentiation and maturation of brain networks in term and preterm newborns (Watanabe et al., 
1999). In acute brain insult, electroencephalographic (EEG) activity shows various degrees of 
depression, and its severity parallels the magnitude of the brain lesion. These ‘acute-stage’ 
abnormalities gradually improve with time and are replaced by ‘chronic-stage’ abnormalities such as 
dysmaturity and disorganisation of the EEG pattern (Klebermass et al., 2011). In the weeks following 
preterm birth, IUGR infants reportedly have altered EEG and amplitude integrated EEG, which has 
been correlated with poor neuromotor development (Yerushalmy-Feler et al., 2014;Schwindt et al., 
2015). In contrast, another study found that the subset of stable preterm IUGR with good clinical 
indices had more mature EEG patterns compared to the AGA peers (Benavente-Fernandez et al., 
2017), and similarly, preterm IUGR infants had accelerated EEG power spectrum maturation 
compared to preterm AGA controls at 1 month post-term equivalent age (Cohen et al., 2018). 
However, no differences were observed at six months’ post-term age between preterm IUGR and 
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AGA infants, or in comparison to a term AGA group, suggesting such changes may resolve with time 
(Cohen et al., 2018). Notably, using visual evoked potentials as an indicator of brain myelination in 
preterm infants born at less than 33 weeks of gestation age, shorter visual evoked potential latency, 
suggestive of increased myelination, was found at 6 months post-term age in IUGR infants who had 
fetal Doppler parameters showing brain sparing (Scherjon et al., 1996). The shorter latency was no 
longer detected at 12 months of post-term age and visual functioning was not affected when followed 
up at 11 years of age (Kok et al., 2007). These findings suggested transient accelerated 
neurophysiological maturation in the IUGR infant brain, possibly as an adaptive process to the severe 
fetal growth restriction. Overall, it appears there are temporal EEG characteristics in IUGR infants 
which may relate to their neurodevelopmental outcome. However, EEG data on preterm infants with 
IUGR are few, as are studies that link EEG parameters with MRI-derived tractography. Early and 
prolonged continuous recording in larger populations would be required to clarify the prognostic value 
of EEG in IUGR infants. 
 
 
INNOVATIONS FOR USE IN IUGR RESEARCH:  
 
Nanomedicine approaches  
 
Engineered nanomaterials offer therapeutic options as diverse as implantable monitoring devices, 
drug delivery scaffolds, and wound dressings. An excellent review on nanomaterials for perinatal 
applications was recently published (Fournier et al., 2018), but we will highlight ways in which these 
approaches could be employed to improve infant neurological outcomes in the context of IUGR. The 
greatest need for the IUGR foetus is safe, effective therapies that can be delivered as early as 
possible in gestation and without the need for preterm delivery. As such, we should turn our attention 
to nanomedicine approaches if these can be maternally delivered and directly affect the function of 
the placenta. Nanoparticles delivered intravenously can cross the placenta, and are found in the 
foetus, including in the non-human primate (see references in Menezes et al., 2011). They can also 
be found in the foetus when administered intranasally to pregnant rats (Campagnolo et al., 2017). A 
recent study monitored the 'protein corona' of polystyrene nanoparticles, which is the spontaneously 
adsorbed protein on the nanoparticle surface when the nanoparticles were exposed to maternal 
plasma. They found that the protein corona formed by maternal serum included vesicular transport 
proteins such as clathrin, tubulin, actin and Ras. As such, rather than pose any barrier to 
transmigration, maternal serum proteins increase the transport of the polystyrene nanoparticles 
across the ex vivo placenta (Gruber et al., 2017). However, in the pregnant rat, inhaled silver 
nanoparticles caused increased fetal resorption and increased expression of placental inflammatory 
markers (Campagnolo et al., 2017). Although this silver nanoparticle study suggests caution in the 
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application of nanoparticles, we can overcome these problems via our ability to modulate the size, 
physical composition, charge and delivery method of nanoparticles. Of note, another recent study has 
shown success in reducing fetal inflammation and neonatal brain injury in a mouse model which 
mimics exposure to inflammation in the preterm infant. Specifically, polyamidoamine dendrimers were 
used to carry the anti-oxidant n-acetylcysteine into the blood of the dam (Lei et al., 2017). This 
dendrimer treatment was associated with improvements in inflammatory and neuropathology indices 
in the fetal compartments. It is important to note that these polyamidoamine dendrimers did not need 
to pass to the foetus to be neuroprotective and thus, this maternal-placental delivery reduces any 
potential of off-target, damaging effects of stray nanoparticles in the foetus.  
 
Work from our lab has taken the approach of targeting one cell type – microglia - rather than being 
compartment-specific (Van Steenwinckel et al., 2018). Microglia are regularly found to mediate injury 
in neurological paradigms. The microglia-specific nanoparticles in our work are comprised of DNA, 
further demonstrating the flexibility in the design possibilities of nanoparticles. However, we do not 
yet know if these DNA nanoparticles cross the placenta, and what specific aspect of microglial 
activation would be the most appropriate to target in IUGR. There is a lack of knowledge of 
nanoparticle biodistribution in non-human primates, or other species with more human-like placental 
structures, such as the spiny mouse (O'Connell et al., 2013). More studies using IUGR models 
developed in species with a more human-like placental structure would be valuable steps towards 
uncovering the potential of nanoparticles to deliver anti-oxidants, vasodilators, or growth factors to 
specifically target pathological processes in the placenta. 
 
Altogether these tools and approaches show that we have made the technological advances and 
have the monitoring skills with which to move forward to design targeted therapies for the placenta 
and the foetus to overcome the damage associated with IUGR. 
 
Using advanced imaging and histology techniques  
 
We have a poor understanding of the direct correspondence between medical imaging outputs and 
tissue microstructure. This lack of knowledge is due to differences in scale and resolution between 
medical imaging modalities and traditional neuropathology techniques that have been further 
frustrated with complexities of image registration (Singh et al., 2008). A lack of knowledge of the 
actual biological substrate of imaging outputs frustrates our ability to understand the specific nature 
of changes occurring in the IUGR infant brain, as the most severely affected infants do not survive, 
as discussed above. Improvements in histological techniques, specifically the use of optically clear 
histology, is allowing us to overcome some of these hurdles (Chung et al., 2013), but obviously not in 
living tissue. Optically clear histology allows whole brains from small experimental animals, and 
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sections of human post-mortem tissue, to be made optically clear and stained with multiple specific 
markers of various cell types. This advance allows us to visualise the 3D organisation of tissue 
microstructure in tissue sections large enough to be studied beforehand with MRI techniques, and 
then to co-register the imaging and histological data. This approach has been applied to the 
developing mouse brain to provide data on what types of cells or cell compartments contribute to 
specific imaging signals (Stolp et al., 2018). A finding from this study worth noting is a positive 
correlation between mean MRI diffusivity and cell density, which is unexpected based on the current 
assumption that cells provide an impediment to the diffusion of water molecules in tissue (Stolp et al., 
2018). This and other findings suggest that a great deal of work in human post-mortem tissues is 
required to ensure that our assumptions of the microstructural correlates of human imaging in the 
literature are robust (Ball et al., 2013;Kelly et al., 2016).  
 
The current gold standard for functional brain imaging is blood–oxygen dependent (BOLD) signals 
measured using MRI (Gore, 2003), but this technique is costly and practically difficult to use in infants. 
An easier to implement optical imaging alternative is functional near-infrared spectroscopy (fNIRS), 
which also measures the level of blood oxygenation and can be applied on neonates or young children 
through the skull but with spatial resolution measured in mm (Meek, 2002). The next level of 
technological development is functional ultrasound (fUS) neuroimaging that provides high sensitivity 
imaging, with a resolution of ~100um, and can identify cerebral blood volume changes in the whole 
brain without contrast agents. The fUS image is based on the phenomenon of neurovascular coupling, 
about which little is known in the developing brain (see, Nakamura et al., 2017b;a for recent animal 
studies) and the ability to measure cerebral blood volume changes with high sensitivity, which is an 
attribute of fUS (Mace et al., 2011). Non-invasive fUS imaging of brain activity in humans is possible 
through the fontanel of human neonates at the bedside. In combination with surface EEG recordings 
in preterm babies, fUS allowed for the estimation of cerebral blood volume variations to measure the 
spatiotemporal dynamics of epileptic seizures (Demene et al., 2017). The sensitivity of fUS, such as 
measuring small diameter blood flow even in rodents with millisecond temporal resolution,  should 
allow it to become a useful and valuable tool to understand the effects of IUGR on the brain in clinical 
and in preclinical settings. We have applied fUS to study the brains of rats in a paradigm of protein 
restriction-induced IUGR and found that it identified connectivity deficits (Rideau Batista Novais et al., 
2016), and was able to validate improvements in connectivity associated with neuroprotection. For 
further comprehensive information on the applications of fUS, please see the recent review by 
Deffieux and colleagues (2018).  
 
Genomic analysis as a means to diagnose, stratify risk and understand disease mechanisms  
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Genomic screening offers the promise of early and specific diagnosis, risk stratification and 
personalised therapeutic deployment. There are inherent ethical issues with genetic screening that 
are in no way limited to the field of IUGR. These include incidental findings of unknown significance 
and the more complex issue of the rights of the child, and specifically the child’s right ‘not to know’. 
Violations of the child's rights may relate to the discovery of gene variants that have no bearing on 
fetal development or childhood health, but which alter adult disease risk. Although generally these 
problems are overcome with targeted analysis, variants with impact at multiple stages of life make 
this problem harder to manage. For a lively discussion on bioethics related to prenatal genome 
sequencing we refer the reader to these references (Berkman and Bayefsky, 2017;Chen and 
Wasserman, 2017;Rhodes, 2017).  
 
Despite these concerns, non-invasive prenatal screening (NIPS) for fetal aneuploidies using cell-free 
DNA has been widely adopted in clinical practice due to its improved accuracy compared to traditional 
screening approaches (Norton et al., 2015). NIPS approaches can include whole genome sequencing 
techniques with high sensitivity and specificity even with very low sample input (Artieri et al., 2017). 
The benefits of whole-genome sequencing include the identification of micro-deletions that would be 
missed by karyotyping. These micro-deletions are relevant to human growth and have identified some 
genetic causes of IUGR (Luo et al., 2017). It might not be necessary to sequence the genome to 
identify disease risk but to examine single nucleotide polymorphisms (SNPs). SNP analysis is 
increasingly accessible with sequencing, and whole-genome SNP arrays can be processed within 3 
days (Srebniak et al., 2011). This short time frame means that the data can affect prenatal diagnostic 
decisions, and in the future, may guide treatment decisions. An approach to risk stratification has 
been tested in the related field of preterm birth, identifying an unbiased association of SNPs with white 
matter imaging phenotype. This approach has successfully identified several SNPs that associate 
with a clinical white matter phenotype in preterm infants – namely, specific SNPs within the genes for 
FADS2 (Fatty Acid Desaturase 2) (Krishnan et al., 2016), PPARG (Peroxisome proliferator-activated 
receptor gamma) (Krishnan et al., 2017b) and DLG4 (discs large homolog 4, the gene Post-Synaptic 
Protein-95 ) (Krishnan et al., 2017a). Although these SNPs provide a biomarker for infant outcome, 
they are also under further investigation to understand the mechanistic link between these genes 
variants and brain development.  
 
What is lacking in the field of IUGR to date is the application of these genomics approaches in massive 
populations to identify variants denoting risk of obstetric and (neuro)developmental outcomes. In the 
fields of Alzheimer’s disease and cancer, it has taken the study of many thousands of patients (and 
their tumours) to identify risk phenotypes that are now used to drive drug discovery efforts and to 
identify targets for personalised drug therapy, and these approaches have been effective in public 
health (Freudenberg-Hua et al., 2018). Altogether, dramatic improvements in technology open 
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avenues for understanding three important aspects of IUGR – diagnosis, risk stratification, and 
mechanisms of disease. The logistical and monetary support to bring together a vast number of 
patients across multiple centres, and the bioinformatics needed to understand these processes, are 
now within reach if we apply the lessons from genetics studies of adult diseases.  
 
Conclusion 
 
IUGR remains a complex health care issue across the globe. Concerted research and clinical effort 
have raised the profile of this complex problem and improved our knowledge of the 
neurodevelopmental sequelae of IUGR. What we cannot yet offer in the field of IUGR is an animal 
model that recapitulates the underlying pathophysiology of IUGR, primarily because we do not yet 
know the aetiology (probably, more than one aetiology) underlying the various sub-groups of IUGR. 
Valuable post-mortem studies, imaging studies using newly optimised in utero foetal and placental 
imaging, and pooling our research data across models to find common elements, will be key to 
overcoming this hurdle. Optimised foetal and placental imaging will also be important future methods 
of early diagnosis and risk stratification. These will enable us to treat the IUGR infant in utero with the 
goal of preventing brain injury rather than attempting postnatal repair or regeneration. We do not yet 
understand the role of neuroinflammation in the human IUGR infant, and as such cannot determine if 
the multitude of immunomodulatory drugs being fast-tracked in fields such as multiple sclerosis and 
Alzheimer’s disease apply to the IUGR infant. The role of neuroinflammation can be studied by 
bringing together multiple models capturing many facets of IUGR-related neurodevelopmental injury, 
and more post-mortem studies. We are also limited in our ability to target drugs to either the placenta 
or the foetus, but these issues will be overcome by advances in materials bioengineering, and proof-
of-concept drugs and tools entering the fields of adult medicine. Given the vast numbers of infants 
born IUGR due to preventable causes such as malnutrition, malaria, HIV infection, and even 
psychosocial stress such as domestic abuse, we already have a mandate to reduce its impact across 
the world. Initiatives such as the Millennium Development Goals are making significant improvements 
in these areas but require our further support. 
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Figure legends 
 
Figure 1: Outline of the causes of IUGR including contributions from maternal, placental and umbilical 
cord and fetal dysfunction or injury. Adapted from Vijayaselvi and Cherian (2017) and Gaccioli and 
Lager (2016) 
 
Figure 2: Representation of the physical presentation of symmetrical and asymmetrical IUGR and a 
short list of clinical characteristics and causes. * note that incidence data are from high-resource 
settings. A third phenotype is proposed in low-resource settings, that includes characteristics of 
malnutrition and late gestation placental insufficiency (Sharma, D., et al., 2016), not shown. # 
Ponderal index = (birthweight (g)/length(cm)3
 
x 100). HC, head circumference. AC, Abdominal 
circumference. GW, gestational weeks. AC, abdominal circumference. EFW, Estimated fetal weight. 
Delphi criteria from Gordijn, S. J., et al. (2016). 
 
 
 
